269 related articles for article (PubMed ID: 9270571)
1. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
2. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
4. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
[TBL] [Abstract][Full Text] [Related]
5. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
6. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
7. Effect of D1 receptor stimulation in normal and MPTP monkeys.
Bédard PJ; Boucher R
Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
[TBL] [Abstract][Full Text] [Related]
8. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
[TBL] [Abstract][Full Text] [Related]
9. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Samadi P; Grégoire L; Bédard PJ
Neuropharmacology; 2003 Dec; 45(7):954-63. PubMed ID: 14573388
[TBL] [Abstract][Full Text] [Related]
10. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Ni L
J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
12. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
[TBL] [Abstract][Full Text] [Related]
13. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
14. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
15. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
[TBL] [Abstract][Full Text] [Related]
16. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
[TBL] [Abstract][Full Text] [Related]
18. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
19. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
20. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Gomez-Mancilla B; Bédard PJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
